IRIS
IACOBELLI, Stefano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.300
EU - Europa 5.887
AS - Asia 5.709
SA - Sud America 741
AF - Africa 83
Continente sconosciuto - Info sul continente non disponibili 13
OC - Oceania 4
Totale 20.737
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.174
SG - Singapore 2.430
CN - Cina 1.537
UA - Ucraina 971
IE - Irlanda 851
GB - Regno Unito 762
RU - Federazione Russa 692
SE - Svezia 639
BR - Brasile 622
TR - Turchia 604
FR - Francia 595
IT - Italia 546
VN - Vietnam 480
DE - Germania 370
IN - India 284
FI - Finlandia 220
CA - Canada 67
HK - Hong Kong 61
PL - Polonia 51
BE - Belgio 44
AR - Argentina 43
IQ - Iraq 43
JP - Giappone 43
BD - Bangladesh 41
MX - Messico 39
KR - Corea 32
ZA - Sudafrica 32
NL - Olanda 28
ES - Italia 27
CZ - Repubblica Ceca 22
UZ - Uzbekistan 21
AT - Austria 19
PK - Pakistan 17
ID - Indonesia 16
VE - Venezuela 15
EC - Ecuador 14
LT - Lituania 13
CO - Colombia 12
IR - Iran 12
EG - Egitto 11
EU - Europa 11
SA - Arabia Saudita 11
AE - Emirati Arabi Uniti 10
IL - Israele 10
PE - Perù 10
MA - Marocco 9
JO - Giordania 8
PH - Filippine 8
PY - Paraguay 8
UY - Uruguay 8
AL - Albania 7
CH - Svizzera 7
KE - Kenya 7
TN - Tunisia 7
AZ - Azerbaigian 6
CL - Cile 6
GR - Grecia 5
NP - Nepal 5
DO - Repubblica Dominicana 4
LB - Libano 4
PT - Portogallo 4
RO - Romania 4
SN - Senegal 4
AO - Angola 3
AU - Australia 3
DZ - Algeria 3
ET - Etiopia 3
JM - Giamaica 3
KG - Kirghizistan 3
MY - Malesia 3
OM - Oman 3
RS - Serbia 3
TH - Thailandia 3
TT - Trinidad e Tobago 3
TW - Taiwan 3
BH - Bahrain 2
BO - Bolivia 2
CR - Costa Rica 2
GE - Georgia 2
HN - Honduras 2
HU - Ungheria 2
NG - Nigeria 2
NI - Nicaragua 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BA - Bosnia-Erzegovina 1
BY - Bielorussia 1
CY - Cipro 1
DK - Danimarca 1
GD - Grenada 1
GT - Guatemala 1
GY - Guiana 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
MK - Macedonia 1
ML - Mali 1
NZ - Nuova Zelanda 1
PA - Panama 1
PR - Porto Rico 1
PS - Palestinian Territory 1
Totale 20.732
Salva come PNG Salva come JPEG
Città #
Singapore 1.806
Jacksonville 1.062
Chandler 1.053
San Jose 861
Dublin 844
Southend 558
Ashburn 461
Dallas 405
Princeton 385
Beijing 342
Izmir 329
Nanjing 307
Los Angeles 229
Santa Clara 221
The Dalles 189
Cambridge 177
Wilmington 177
Ho Chi Minh City 150
Tongling 140
Boardman 134
Ann Arbor 127
New York 115
Buffalo 112
Nanchang 111
Dearborn 105
Hanoi 101
Altamura 91
Moscow 87
Chieti 66
Council Bluffs 64
Munich 62
Woodbridge 62
São Paulo 61
Hebei 53
Hong Kong 51
Shenyang 50
Tianjin 46
Brussels 43
Pescara 43
Kunming 42
Orem 41
Tokyo 38
Redondo Beach 37
Houston 36
Brooklyn 33
Chennai 33
Stockholm 32
Seoul 30
Warsaw 30
Boston 29
Denver 29
Jiaxing 29
London 29
Montreal 28
Norwalk 26
Atlanta 25
Chicago 25
Dong Ket 24
Poplar 24
Hangzhou 23
Hefei 23
Johannesburg 23
Nuremberg 23
Changsha 22
Helsinki 21
Manchester 20
Rome 20
Tashkent 20
Da Nang 19
Falls Church 19
Frankfurt am Main 19
Kocaeli 19
Grevenbroich 18
Turku 18
Brno 17
Montesilvano 17
Baghdad 16
Collecorvino 16
Haiphong 16
San Francisco 16
Washington 16
Phoenix 15
Rio de Janeiro 15
San Mateo 15
Amsterdam 14
Belo Horizonte 14
Hyderabad 14
Jinan 14
Kraków 14
Lanzhou 14
Orange 14
Augusta 13
Leawood 13
Mumbai 13
Milan 12
Ankara 11
Auburn Hills 11
Campinas 11
Lappeenranta 11
Salvador 11
Totale 12.570
Salva come PNG Salva come JPEG
Nome #
A phase I study of recombinant interferon-alpha administered as a seven-day continuous venous infusion at circadian-rhythm modulated rate in patients with cancer. 205
90K (Mac-2 BP) in human milk 196
90K (Mac-2 BP) and galectins in tumor progression and metastasis. 181
EV20-mediated delivery of cytotoxic auristatin MMAF exhibits potent therapeutic efficacy in cutaneous melanoma 177
A comparative study of the antiinflammatory, anticoagulant, antiangiogenic, and antiadhesive activities of nine different fucoidans from brown seaweeds 172
EV20-Sap, a novel anti-HER-3 antibody-drug conjugate, displays promising antitumor activity in melanoma 171
Breast cancer "tailored follow-up" in Italian oncology units: A web-based survey 170
A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer. 164
An immunohistochemically positive E-cadherin status is not always predictive for a good prognosis in human breast cancer. 164
90K (MAC-2 BP) gene expression in breast cancer and evidence for the production of 90K by peripheral-blood mononuclear cells 163
Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients 163
Prognostic relevance of LGALS3BP in human colorectal carcinoma 159
Functional and prognostic significance of the genomic amplification of frizzled 6 (FZD6) in breast cancer 158
The 90K tumor associated antigen and clinical progression in human immunodeficiency virus infection 157
A phase I study of 5-day continuous venous infusion of carboplatin (CBDCA) at circadian rhythm-modulated rate 156
90K (Mac-2 BP) predicts CD4 decline in human immunodeficiency virus-infected patients with CD4 counts above 200 x 10^6 cells/L 153
ERBB3 BINDING ANTIBODY 152
90K protein in HIV infection: evidence of its release from peripheral blood mononuclear cells 151
A phase II study of cisplatin, epirubicin, vindesine chemotherapy and lonidamine in advanced nonsmall cell lung cancer 151
90k is a serum marker of poor-prognosis in non-hodgkins-lymphoma patients. 149
ErbB-3 activation by NRG-1β sustains growth and promotes vemurafenib resistance in BRAF-V600E colon cancer stem cells (CSCs) 149
Secreted Gal-3BP is a novel promising target for non-internalizing Antibody–Drug Conjugates 149
Analisi dello stato mutazionale di K-RAS: un nuovo strumento per la selezione dei pazienti candidati a terapia con anticorpi anti-EGFR 147
Generation of a novel Antibody-Drug Conjugate targeting endosialin: potent and durable antitumor response in sarcoma 147
The 90K protein increases major histocompatibility complex class I expression and is regulated by hormones, gamma-interferon, and double-strand polynucleotides. 146
Overexpression of PY1289-HER3 in sporadic pulmonary carcinoid from patients bearing MEN1 gene variants 145
New Targets for Therapy in Pancreatic Cancer 144
Elevated serum levels of 90K/MAC-2BP predict unresponsiveness to alfa-interferon therapy in chronic HCV hepatitis patients 143
Purification and characterization of a 90 kDa protein releasedfrom human tumors and tumor cell lines 143
An Epigenetic Approach to Pancreatic Cancer Treatment: the Prospective Role of Histone Deacetylase Inhibitors 142
High expression of 90K (Mac-2 BP) is associated with poor survival in node-negative breast cancer patients not receiving adjuvant systemic therapies 141
A PHASE II STUDY OF NEOADJUVANT CHEMOTHERAPY WITH CISTAPLIN, EPIRUBICIN AND VP – 16 FOR STAGE III UNRESECTABLE NON-SMALL CELL LUNG CANCER 138
A 90-kDa protein serum marker for the prediction of progression to AIDS in a cohort of HIV-1+ homosexual men. 138
Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice. 135
Anthropometric, clinical and molecular determinants of treatment outcomes in postmenopausal, hormone receptor positive metastatic breast cancer patients treated with fulvestrant: Results from a real word setting 133
Dual targeting of ErbB-2/ErbB-3 results in enhanced antitumor activity in preclinical models of pancreatic cancer. 132
Upstream stimulatory factor regulates constitutive expression and hormonal suppression of the 90K (Mac-2BP) protein. 131
A Stochastic Model for the HIV/AIDS Dynamic Evolution 130
HPLC-DAD validated method for DM4 and its metabolite S-Me-DM4 quantification in biological matrix for clinical and pharmaceutical applications 129
Novel inhibitors of pvhl-elongin c binding 129
Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer 128
Expression of tumor associated 90K-antigen in human breast cancer: no correlation with prognosis and response to first-line therapy with tamoxifen 127
Adhesion to 90K (Mac-2 BP) as a mechanism for lymphoma drug resistance in vivo. 127
90K protein: a new predictor marker of disease progression in human immunodeficiency virus infection. 126
Inhibition of tumor growth and angiogenesis by SP-2, an anti-lectin, galactoside-binding soluble 3 binding protein (LGALS3BP) antibody. 126
Pharmacokinetics of pegylated liposomal doxorubicin administered by intraoperative hyperthermic intraperitoneal chemotherapy to patients with advanced ovarian cancer and peritoneal carcinomatosis 126
Arterial Thrombosis in ambulatory cancer patients treated with chemotherapy. 126
Patterns of K-ras mutation in colorectal carcinomas from Iran and Italy (a Gruppo Oncologico dell'Italia Meridionale study): influence of microsatellite instability status and country of origin. 124
Chronomodulated infusion of cisplatin, 5-fluorouracil and folinic acid: lack of activity in advanced colorectal cancer. 124
Targeting vesicular lgals3bp by an antibody-drug conjugate as novel therapeutic strategy for neuroblastoma 124
Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival 123
Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts. 123
DNA ploidy and S-phase fraction in pulmonary carcinoids. 121
HER-3 surface expression increases in advanced colorectal cancer representing a potential therapeutic target 120
Prognostic value of 90K protein in HIV infection 120
Tyrosine kinase inhibitors 120
Surgical treatment of adrenal metastases from non small cell lung cancer 119
Asymptomatic venous thromboembolism in patients with solid tumors treated with chemotherapy: An underestimated phenomenon 119
Axillary Lymph Node Nanometastases are Prognostic Factors for Disease-Free Survival and Metastatic Relapse in Breast Cancer Patients 118
[Hairy cell leukemia: prognosis and treatment] 117
Unknown primary tumors 116
Bone marrow micrometastases detected by a monoclonal antibody in patients with breast cancer. 116
Role of 90K protein in asthma and TH2-type cytokine expression. 115
Concentrations of Galectin-3 in the Sera of Normal Controls and Cancer Patients 115
Lack of prognostic value of immunohistochemical determination of epidermal growth-factor receptors in human prostate-cancer. 115
Tumor-derived microvesicles: The metastasomes. 115
EV20‑sss‑vc/MMAF, an HER‑3 targeting antibody‑drug conjugate displays antitumor activity in liver cancer 115
Prognostic value of a novel circulating serum 90K antigen in breast cancer 114
Prognostic value of gender and primary tumor location in metastatic colon cancer 114
Increased levels of soluble P-selectin in hypercholesterolemic patients 113
Prognostic value of a novel circulating serum 90K antigen in HIV-infected haemophilia patients. 113
Relief of symptoms after gefitinib is associated with improvement of rest/activity rhythm in advanced lung cancer 112
A multicenter phase II study of Epirubicin with low-dose Herceptin as a first line treatment in HER-2 overexpressing metastatic breast cancer 112
Incidental venous thromboembolism in ambulatory cancer patients receiving chemotherapy 110
Unusually high level of a tumor-associated antigen in the serum of human immunodeficiency virus-seropositive individuals. 110
The use of pegylated liposomal doxorubicin with hyperthermic intraperitoneal chemotherapy(HIPEC) in patients undergoing cytoreductive surgery (CS) for peritoneal carcinomatosis ofovarian origin 110
Elevated Plasma Levels of 90K (Mac-2 BP) Immunostimulatory Glycoprotein in HIV-1-Infected Children 109
Expression of the 90K tumor-associated protein in benign and malignant melanocytic lesions. 109
Synthetic lactulose amines: novel class of anticancer agents that induce tumor-cell apoptosis and inhibit galectin-mediated homotypic cell aggregation and endothelial cell morphogenesis. 109
A stochastic model for evaluating the HIV anti-retroviral treatment patient cost: a case study 109
Preclinical validation of 3-phosphoinositide-dependent protein kinase 1 inhibition in pancreatic cancer 109
An ErbB-3 antibody, MP-RM-1, inhibits tumor growth by blocking ligand-dependent and independent activation of ErbB-3/Akt signaling. 109
Anti-LGALS3BP antibody-drug conjugate treatment induces durable and potent antitumor response in a preclinical model of adenoid cystic carcinoma 108
Lack of expression of galectin-3 is associated with a poor outcome in node-negative patients with laryngeal squamous-cell carcinoma. 108
Combined therapy in pancreatic cancer 108
Flavonoids inhibit melanoma lung metastasis by impairing tumor cells endothelium interactions. 108
Phospholipase Cgamma1 is required for metastasis development and progression 108
The mechanism involved in the regulation of phospholipase Cgamma1 activity in cell migration. 108
HCV genotype and serum 90K levels: host and virus related factors predict response to a-ifn therapy 107
Pancreatic juice 90K and serum CA 19-9 combined determination can discriminate between pancreatic cancer and chronic pancreatitis. 107
Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones. 107
Molecular mechanisms of endocrine resistance and their implication in the therapy of breast cancer 106
Extracellular LGALS3BP: a potential disease marker and actionable target for antibody-drug conjugate therapy in glioblastoma 105
Dynamic test with recombinant interferon-alpha-2b: effect on 90K and other tumour-associated antigens in cancer patients without evidence of disease. 104
Neoadjuvant chemotherapy with cisplatin, epirubicin and VP-16 for stage IIIA-IIIB non-small-cell lung cancer: a pilot study. 104
A multicentre, double-blind, randomised trial comparing ondansetron versus ondansetron plus dexamethasone in the prophylaxis of cisplatin-induced delayed emesis. 104
Tumor-associated antigen 90K activates myelomonocytic cell line THP-1 103
Oral etoposide and platinum derivates in the treatment of metastatic Merkel cell carcinoma: report of three cases 103
Preoperative dose-dense sequential chemotherapy of epirubicin/cyclophosphamide followed by docetaxel/capecitabine in patients with breast cancer 102
Immunohistochemical and serological 90K/Mac-2BP detection in hepatocellular carcinoma patients: different behaviour of two monoclonal antibodies 102
Totale 12.932
Salva come PNG Salva come JPEG
Categoria #
all - tutte 76.081
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 76.081
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021337 0 0 0 0 0 0 0 0 0 194 82 61
2021/2022739 11 12 5 137 90 16 15 52 65 14 93 229
2022/20232.806 210 288 173 356 315 597 159 220 329 25 73 61
2023/20241.213 109 37 99 58 67 356 261 39 14 23 16 134
2024/20253.627 200 751 610 90 64 97 124 189 320 186 402 594
2025/20266.127 553 358 707 796 572 491 1.119 374 672 485 0 0
Totale 21.135